Angiogenesis

, Volume 3, Issue 2, pp 147–158

Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: Effect on human microvascular endothelial cell proliferation and angiogenesis

Authors

  • Kalpna Gupta
    • Department of MedicineUniversity of Minnesota Medical School
  • Pankaj Gupta
    • Department of MedicineUniversity of Minnesota Medical School
    • Department of MedicineVeterans Administration Medical Center
  • Robert Wild
    • Department of PharmacologyUniversity of Minnesota Medical School
  • Sundaram Ramakrishnan
    • Department of PharmacologyUniversity of Minnesota Medical School
  • Robert P. Hebbel
    • Department of MedicineUniversity of Minnesota Medical School
Article

DOI: 10.1023/A:1009018702832

Cite this article as:
Gupta, K., Gupta, P., Wild, R. et al. Angiogenesis (1999) 3: 147. doi:10.1023/A:1009018702832

Abstract

Vascular endothelial growth factor (VEGF) is a specific angiogenic factor, and thrombospondin (TSP), is a potent inhibitor of angiogenesis. To better understand the role of TSP as an anti-angiogenic agent, we have identified its specific domains that participate in its anti-angiogenic activity and examined the mechanism of its inhibitory effect on VEGF165 induced angiogenesis. Exogenously added TSP inhibited VEGF165 induced angiogenesis (proliferation and tube formation of human dermal microvascular endothelial cells {HDMEC} and neovascular outgrowth from human arterial rings). Although both VEGF165 and TSP are heparin binding proteins, TSP had a higher affinity for 125I-heparin than VEGF165 (Kd1 4 nM and Kd2 14 nM for TSP; Kd 91 nM for VEGF165). TSP displaced 36% of 125I-VEGF165 from HDMEC and this was comparable to the 27% reduction in 125I-VEGF165 binding to HDMEC upon cleavage of cell surface heparan sulfate (HS). About 35% of the mitogenic activity of VEGF165 was attributable to its heparin binding region. These results indicate that a proportion of the mitogenic activity of VEGF165 is inhibited by TSP via competition for cell surface HS. Further, 125I-VEGF165 bound directly to TSP in a saturable, concentration dependent manner, and heparin modulated this binding. The mAbs to the heparin binding domain to the type 1 and type 3 repeats of TSP inhibited the binding of VEGF165 to TSP, and also blocked the inhibitory effect of TSP on VEGF165 induced HDMEC proliferation. We conclude that (i) the anti-angiogenic activity of TSP is localized in its heparin binding domain and type 1 and type 3 repeats (ii) TSP inhibits angiogenesis by at least two separate mechanisms, (a) displacement of VEGF165 from endothelial cell HS and (b) direct binding to VEGF165.

angiogenesisendothelial cellheparan sulfatethrombospondinVEGF

Copyright information

© Kluwer Academic Publishers 1999